EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Sean Wharton iD, Adam Stefanski iD, Jiaxun Chen iD, Girish Rao iD, Elvis Asare Twum iD, Max Denning iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71032 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Sean Wharton und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, and Wharton Weight Management Clinic, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Overweight, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed. Materials and Methods Overall, 11 220 participants were included in this analysis (orforglipron N = 6920; pooled comparator [placebo, oral semaglutide, dapagliflozin, insulin glargine] N = 4300) for up to 104 weeks, including safety follow‐up. Eligibility criteria for these Phase 3 trials included ALT/AST < 3 × ULN in the weight management programme and ≤ 5 × ULN in the T2D programme. The main analysis sets included placebo‐controlled trials by indication for pooled orforglipron doses. Changes from baseline in hepatic analytes were assessed continuously and categorically, and screening for drug‐induced liver injury/Hy's Law was conducted. Hepatic AEs were summarised. Subgroup analyses were conducted in participants with elevated baseline aminotransferases.

Results

Orforglipron treatment was associated with mean reductions in ALT/AST. Categorical ALT/AST elevations were generally balanced between orforglipron and comparators. Six (0.1%) orforglipron‐treated participants and six (0.1%) comparator‐treated participants had ALT or AST ≥ 3 × ULN and TBIL ≥ 2 × ULN; however, alternative etiologies accounted for all orforglipron cases and thus did not meet criteria for drug induced liver injury/Hy's Law. The incidence of hepatic AEs was balanced between orforglipron and pooled comparators, suggesting no increased risk with orforglipron. Results were consistent in participants with normal and elevated baseline aminotransferases.

Conclusions

In this pooled analysis of orforglipron Phase 3 clinical trials, orforglipron treatment was not associated with drug‐induced liver injury, demonstrating a hepatic safety profile similar to placebo or active comparators. There were no cases consistent with drug‐induced liver injury/Hy's Law with orforglipron. Aminotransferase trajectories showed a hepatic profile consistent with the metabolic benefits of weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityOverweightHypoglycemic AgentsChemical and Drug Induced Liver InjuryLiverHumansFemaleMaleMiddle AgedAdultSemaglutideClinical Trials, Phase III as TopicAlanine TransaminaseAgedGlucosidesInsulin GlargineGlucagon-Like PeptidesBenzhydryl CompoundsOxadiazolesFluorine Compounds

Stichwörter der Autor:innen

ACHIEVEATTAINhepatic safetyobesityorforgliprontype 2 diabetes

Substanzen

SemaglutideHypoglycemic AgentsAlanine TransaminaseGlucosidesInsulin GlargineGlucagon-Like PeptidesdapagliflozinorforglipronBenzhydryl CompoundsOxadiazoles

Autor:innen und Institutionen

  • University of Toronto, and Wharton Weight Management Clinic, Toronto, Ontario, Canada.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning

Förderung

  • Eli Lilly and Company

Zitieren

APA

Wharton, S., Stefanski, A., Chen, J., Rao, G., Twum, E. A., & Denning, M. (2026). Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71032

Vancouver

Wharton S, Stefanski A, Chen J, Rao G, Twum EA, Denning M. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71032

BibTeX
@article{Wharton2026,
  author = {Wharton, Sean and Stefanski, Adam and Chen, Jiaxun and Rao, Girish and Twum, Elvis Asare and Denning, Max},
  title = {Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71032}
}
Kostenlos starten →